Literature DB >> 3947514

Antigenicity of newly established colorectal carcinoma cell lines.

L G Durrant, R A Robins, M V Pimm, A C Perkins, N C Armitage, J D Hardcastle, R W Baldwin.   

Abstract

Cells from two adenocarcinomas, an adenoma and a metastatic node were isolated in soft agar. Expression of antigens, CEA, Y haptenic blood group and 791T-p72, defined by a range of candidate antibodies for tumour targeting was assessed. All of the cells expressed low levels of CEA but high levels of the Y haptenic blood group antigen although there was enormous inter and intraclonal variation. Of particular interest was the membrane expression of 791T-p72 antigen on all of the dividing tumour cells as previous studies had shown that 791T/36 antibody reacted with tumour stromal elements rather than malignant cell surfaces. The DNA content was abnormal in all of the cells whether they were derived from diploid or aneuploid primary tumours. They all grew readily in athymic mice and at least one monoclonal antibody, 791T/36, localised efficiently within these xenografts. Clonogenic cells therefore expressed the three tumour-associated antigens, several at higher levels than observed in the primary tumour. Monoclonal antibody 'cocktails' should therefore allow antibody mediated drug cytotoxicity to be effective at eradicating rapidly dividing tumour cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947514      PMCID: PMC2001479          DOI: 10.1038/bjc.1986.6

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Variants of a human colon adenocarcinoma cell line which differ in morphology and carcinoembryonic antigen production.

Authors:  K L Rosenthal; W A Tompkins; G L Frank; P McCulloch; W E Rawls
Journal:  Cancer Res       Date:  1977-11       Impact factor: 12.701

2.  A monoclonal antibody against human colonic adenoma recognizes difucosylated Type-2-blood-group chains.

Authors:  A Brown; T Feizi; H C Gooi; M J Embleton; J K Picard; R W Baldwin
Journal:  Biosci Rep       Date:  1983-02       Impact factor: 3.840

3.  Cancer statistics, 1983.

Authors:  E Silverberg
Journal:  CA Cancer J Clin       Date:  1983 Jan-Feb       Impact factor: 508.702

4.  Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro.

Authors:  M C Garnett; M J Embleton; E Jacobs; R W Baldwin
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

5.  Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody.

Authors:  P A Farrands; A C Perkins; M V Pimm; M J Embleton; J D Hardy; R W Baldwin; J D Hardcastle
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

6.  The results of 1115 patients with colorectal cancer treated over an 8-year period in a single hospital.

Authors:  M J Stower; J D Hardcastle
Journal:  Eur J Surg Oncol       Date:  1985-06       Impact factor: 4.424

7.  Heterogeneity of cancer cells from a single human colon carcinoma.

Authors:  D L Dexter; E N Spremulli; Z Fligiel; J A Barbosa; R Vogel; A VanVoorhees; P Calabresi
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

8.  Characteristics of a cell surface antigen defined by an anti-human osteogenic sarcoma monoclonal antibody.

Authors:  M R Price; D G Campbell; R A Robins; R W Baldwin
Journal:  Eur J Cancer Clin Oncol       Date:  1983-01

9.  Phenotypic drift of metastatic and cell-surface properties of mammary adenocarcinoma cell clones during growth in vitro.

Authors:  A Neri; G L Nicolson
Journal:  Int J Cancer       Date:  1981-12       Impact factor: 7.396

10.  Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line.

Authors:  M J Embleton; B Gunn; V S Byers; R W Baldwin
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

View more
  7 in total

1.  Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine.

Authors:  S A Watson; L J Wilkinson; J F Robertson; J D Hardcastle
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

2.  Establishment and characterization of a human colon cancer cell line, OUMS-23, from a patient with familial adenomatous polyposis.

Authors:  M Miyazaki; S Tsuboi; K Mihara; T Kosaka; K Fukaya; K Kino; M Mori; M Namba
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth.

Authors:  W J Adams; J A Lawson; D L Morris
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

4.  Patterns of reactivity of the monoclonal antibody 791T/36 with different tumour metastases in the liver.

Authors:  C J Hawkey; C H Holmes; P G Smith; E B Austin; R W Baldwin
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

5.  Flow cytometric analysis of the DNA content of gastric cancer.

Authors:  K C Ballantyne; P D James; R A Robins; R W Baldwin; J D Hardcastle
Journal:  Br J Cancer       Date:  1987-07       Impact factor: 7.640

6.  Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase.

Authors:  H M Collins; T M Morris; S A Watson
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

7.  Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth.

Authors:  J A Lawson; W J Adams; D L Morris
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.